Antibody-drug conjugates (ADCs) are a promising cancer therapy, delivering potent drugs directly to tumor cells. In this article, Yoonjin Kwon, a Lead Scientist in ADC Analytical Method Development, shares her insights on the challenges and emerging trends in ADC development, drawing from her extensive experience.
Antibody-drug conjugates (ADCs) are a promising cancer therapy, delivering potent drugs directly to tumor cells. In this article, Yoonjin Kwon, a Lead Scientist in ADC Analytical Method Development, shares her insights on the challenges and emerging trends in ADC development, drawing from her extensive experience.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article